COVID-19 Vaccines ‘May Trigger’ Rheumatic Inflammatory Diseases: Study
A new review suggests that COVID vaccines “may trigger” rheumatic immune-mediated inflammatory diseases, including arthritis, vasculitis, lupus, and adult-onset Still’s disease.
On average, patients developed rheumatic diseases 11 days after vaccine administration, according to the study. Seventy-five (over 27 percent) of these patients experienced total disease remission, and about 50 percent improved following treatment. Eight were admitted to intensive care, and two died from their symptoms.
“The short time span between COVID-19 vaccine administration and the onset of R-IMIDs suggests the potential possibility of a cause-and-effect relationship,” the authors wrote.
Rheumatic immune-mediated inflammatory diseases (R-IMIDs) involve inflammation that manifests in the joints, tendons, muscles, and bones due to an unknown cause.
Over 80 percent of the patients developed symptoms after their first or second dose of the COVID-19 vaccine, and most were treated and improved with corticosteroids.
Reported Diseases
Rheumatic diseases may be less common than myocarditis, a known adverse event of COVID vaccination. A search on the Vaccine Adverse Event Reporting System (VAERS) found that over 3,000 cases of myocarditis have been reported after the COVID-19 vaccine, with over 2,300 cases of arthritis, over 370 cases of systemic lupus erythematosus, the most common type of lupus, and 280 cases of vasculitis. The following are rheumatic diseases that were included in this first-ever systematic review of new-onset R-MIDs after COVID vaccination.
Inflammation of Blood Vessels
Vasculitis was the most common rheumatic disease in the review, with 86 adverse events recorded. The more common vasculitis diseases affect the smaller blood vessels, causing red spots and lumps on the skin and possible organ damage. Medium and larger blood vessels can also be affected, causing tissue, muscle, and kidney damage.
Connective Tissue Diseases
Sixty-six cases of diseases affected the connective tissues. Diseases that fall under this category include lupus, an autoimmune disease affecting the skin, joints, and internal organs, and myositis and dermatomyositis, which manifest as muscle and tissue inflammation.
Arthritis
Fifty-five patients developed arthritis after taking the vaccine, primarily manifesting in the knees, elbows, and ankles.
Adult-Onset Still’s Disease
Twenty-two cases of adult-onset Still’s disease were documented in the report. Symptoms of this rare disease include daily fever, arthritis in more than five joints, and salmon-pink rashes on the body. Six of these patients also developed cardiac problems, two of whom developed myocarditis and heart failure.
Other Diseases
Less common diseases include polymyalgia rheumatica, reported in 21 people. Symptoms of this disease include stiffness and inflammation in the shoulders, neck, and hips, and sarcoidosis, which occurs when inflamed tissues start to grow inside organs, causing tissue malfunction.
Molecular Mimicry Is the Leading Explanation
The authors noted the very short duration between vaccination and symptom onset, with 11 days being the average duration. This duration is similar to those found in other studies investigating myocarditis side effects after COVID-19 vaccines. The authors reasoned that the vaccine may have been a “trigger” for the rheumatoid diseases.
However, some of the patients might have been predisposed to rheumatic diseases, the authors reasoned. Additionally, some might have been predisposed to having a highly inflammatory response to mRNA vaccinations, leading to rheumatic symptoms like joint stiffness and inflammation.
Another possibility is that mRNA vaccines may trigger the formation of inflammasomes. Inflammasomes are clusters of proteins that signal inflammation and viral elimination. This can also cause immune cells to become hyperactive and damage self-tissues in an attempt to clear the vaccine.
Source: Epoch Times
Please Donate Below To Support Our Ongoing Work To Expose The Lies About Covid 19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.
schutzhund
| #
It’s called re-activation, and it is exploding.
Reply
nils-ola Holtze
| #
Another pathway the mRNA vaccine can cause disease is by inducing NETosis. White blood cells cast out its chromatin like a net to catch for example a foreign protein. At the same time, it releases inflammasomes and more. If this phenomenon, get overstimulated it can cause inflammation, thrombosis, autoimmune diseases, worsen cancer and much more. A continuous production of a modified spike protein could certainly overstimulate this part of our innate immune defence.
Reply
Wisenox
| #
Once again, they purposely avoid the patents. Well, they happen to be the only place to look, so here’s an explanation that uses them:
Moderna patent 10703789 includes Bancell patent 2015/0030576: Methods for targeting agents into and across the blood brain barrier.
The Bancell patent explains that, in one embodiment, they target the VCAM1 receptor on the vascular endothelium. Once attached, the vascular endothelium expresses cytokines. Cytokines cause inflammation and leukocytes show up to address the issue. The picornavirus in the patent then infects the white blood cell, which activates it causing it to migrate into the CNS and brain. One such picornavirus used is called ‘Encephalomyocarditis virus’, so match that with side effects.
What is VCAM1? From genecards.org:
“This gene is a member of the Ig superfamily and encodes a cell surface sialoglycoprotein expressed by cytokine-activated endothelium. This type I membrane protein mediates leukocyte-endothelial cell adhesion and signal transduction, and may play a role in the development of artherosclerosis and rheumatoid arthritis. ”
Further dives into VCAM1 show that its closely related to SELE and the cytokine signaling pathway. A simple query on Malacards for vasculitis shows the connections to VCAM1 and leukocyte adhesion. The heavy cysteine density found in this process is also relevant to fusion requirements of the PRRA insert described in literature.
Reply